Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Jazz Pharmaceuticals, a specialty pharmaceutical company, has reported that Samuel Saks, its CEO and a member of its board of directors, has resigned from both positions, effective as of April 3, 2009. Dr Saks will serve as a consultant to the company on medical and clinical matters after his departure.
Subscribe to our email newsletter
The board of directors has appointed Bruce Cozadd as the company’s new CEO. Mr Cozadd has been Jazz Pharmaceuticals’s executive chairman, and a member of the board of directors, since the company’s founding in 2003.
From 1991 until 2001, Mr Cozadd held various positions with Alza, a pharmaceutical company now owned by Johnson & Johnson, most recently as its executive vice president and COO, with responsibility for R&D, manufacturing and sales and marketing.
The board of directors has also appointed Robert Myers, Jazz Pharmaceuticals’s president, to the board of directors to fill the vacancy on the board of directors created by Dr Saks’s resignation.
Mr Myers joined Jazz Pharmaceuticals at its inception. He was appointed as Jazz Pharmaceuticals’s president in March 2007. From 2003 until 2007, Mr Myers served as Jazz Pharmaceuticals’s executive vice president and chief business officer.